Vir Biotechnology, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VIR research report →
Companywww.vir.bio
Vir Biotechnology, Inc. , a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus.
- CEO
- Marianne De Backer
- IPO
- 2019
- Employees
- 408
- HQ
- San Francisco, CA, US
Price Chart
Valuation
- Market Cap
- $1.50B
- P/E
- -2.96
- P/S
- 22.87
- P/B
- 1.61
- EV/EBITDA
- -2.93
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 275.25%
- Op Margin
- -704.87%
- Net Margin
- -675.96%
- ROE
- -53.31%
- ROIC
- -48.49%
Growth & Income
- Revenue
- $68.56M · -7.61%
- Net Income
- $-437,987,000 · 16.09%
- EPS
- $-3.16 · 17.49%
- Op Income
- $-468,020,000
- FCF YoY
- 12.57%
Performance & Tape
- 52W High
- $11.66
- 52W Low
- $4.16
- 50D MA
- $9.58
- 200D MA
- $7.01
- Beta
- 1.70
- Avg Volume
- 3.53M
Get TickerSpark's AI analysis on VIR
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 1, 26 | SATO VICKI L | sell | 22,000 |
| Apr 29, 26 | De Backer Marianne | other | 233,532 |
| Apr 29, 26 | De Backer Marianne | other | 233,532 |
| Apr 6, 26 | De Backer Marianne | sell | 72,559 |
| Apr 1, 26 | SATO VICKI L | sell | 22,000 |
| Mar 23, 26 | Sabatini Brent | sell | 7,711 |
| Mar 20, 26 | O'Byrne Jason | other | 2,500 |
| Mar 20, 26 | O'Byrne Jason | other | 2,500 |
| Mar 2, 26 | SATO VICKI L | sell | 21,800 |
| Mar 2, 26 | SATO VICKI L | sell | 200 |
Our VIR Coverage
We haven't published any research on VIR yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate VIR Report →